Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given a consensus rating of “Moderate Buy” by the seven analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $20.3333.

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the company from $14.00 to $20.00 in a research report on Wednesday, October 1st. JPMorgan Chase & Co. assumed coverage on Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 price objective on the stock. Westpark Capital lifted their price objective on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 8th. Finally, JMP Securities raised their price target on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 12th.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently bought and sold shares of ENTA. XTX Topco Ltd acquired a new position in Enanta Pharmaceuticals during the first quarter worth $110,000. US Bancorp DE acquired a new position in shares of Enanta Pharmaceuticals during the first quarter valued at about $36,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Enanta Pharmaceuticals by 3.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 159,801 shares of the biotechnology company’s stock valued at $882,000 after buying an additional 4,974 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Enanta Pharmaceuticals by 23.7% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 30,465 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 5,829 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Enanta Pharmaceuticals by 29.3% in the 1st quarter. Invesco Ltd. now owns 60,277 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 13,663 shares during the last quarter. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Stock Performance

ENTA stock opened at $14.24 on Friday. The company’s 50-day simple moving average is $11.63 and its 200 day simple moving average is $8.94. Enanta Pharmaceuticals has a 52 week low of $4.09 and a 52 week high of $15.34. The company has a market capitalization of $411.01 million, a PE ratio of -3.72 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.26. The business had revenue of $15.13 million during the quarter, compared to analysts’ expectations of $15.60 million. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. On average, analysts forecast that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.